Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro.

ABSTRACT: The integrase strand transfer inhibitor (INSTI)-based regimens bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), dolutegravir (DTG)+FTC/TAF, DTG/lamivudine (3TC), and DTG/rilpivirine (RPV) are all approved for treatment of HIV-infected patients, with various limitations. Here, time to in vitro viral breakthrough (VB) and resistance barrier using simulated human drug exposures at either full or suboptimal treatment adherence to each regimen were compared. At drug concentrations corresponding to full adherence and 1 missed dose (C_min and C_min-1), no VB occurred with any regimen. At C_min-2, VB occurred only with DTG+3TC, with emergent resistance to both drugs. At C_min-3, VB occurred with all regimens:

SUBMITTER: Acosta RK 

PROVIDER: S-EPMC9112893 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature